BeiGene has signed an agreement with DualityBio to acquire an exclusive option for the international clinical and commercial licensing of DualityBio’s antibody-drug conjugate (ADC) therapy for the treatment of certain solid tumours.
The investigational therapy is currently in the preclinical stage.
BeiGene will make an upfront payment to DualityBio upon exercising the option.
DualityBio is entitled to receive further milestone payments of $1.3bn on meeting specific development, regulatory and commercial goals.
BeiGene will hold the international clinical, production and commercial rights for the ADC therapy.
DualityBio will carry out all research through investigational new drug application (IND)-enabling studies and will support Beigene’s future IND submissions.
BeiGene research and development global head Lai Wang stated: “With one of the industry’s leading global oncology research teams, we are investing in highly impactful therapeutic modalities such as ADCs that complement our dynamic and growing pipeline in solid tumours.
“Through this strategic partnership with DualityBio, we are well positioned to advance this asset globally alongside our initial internally discovered ADC assets with our end-to-end ADC manufacturing capabilities.”
The latest development comes after BeiGene entered a strategic collaboration with Chime Biologics and Leads Biolabs to expedite the development of LBL-007, a monoclonal antibody.